3KY:F:F-HANSOH PHARMAC. HD-00001 (EUR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1.88

Change

0.00 (0.00)%

Market Cap

USD 11.57B

Volume

500.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-07 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MRK:F Merck & Company Inc

N/A

USD 69.80B
MRKC:F MERCK KGAA NAM.SP.ADR

-0.20 (-0.65%)

USD 66.96B
H6D0:F Haleon PLC

-0.03 (-0.71%)

USD 43.69B
H6D:F Haleon PLC

-0.05 (-0.54%)

USD 42.63B
TKDA:F Takeda Pharmaceutical Company ..

-0.10 (-0.78%)

USD 41.72B
TEV:F Teva Pharmaceutical Industries..

+0.20 (+1.28%)

USD 17.73B
RDDA:F Dr. Reddy's Laboratories Limit..

N/A

USD 12.13B
SH0:F Shionogi & Co. Ltd

N/A

USD 11.21B
NB3:F Neurocrine Biosciences Inc

-2.10 (-2.04%)

USD 10.43B
0C8:F Catalent Inc

+0.31 (+0.57%)

USD 10.01B

ETFs Containing 3KY:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.63% 67% D+ 74% C
Dividend Return 8.67% 54% F 72% C
Total Return 23.30% 67% D+ 75% C
Trailing 12 Months  
Capital Gain 27.89% 76% C+ 78% C+
Dividend Return 19.29% 53% F 74% C
Total Return 47.18% 76% C+ 80% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 3.75% 72% C 58% F
Dividend Return 4.63% 68% D+ 54% F
Total Return 0.88% 43% F 34% F
Risk Return Profile  
Volatility (Standard Deviation) 14.64% 86% B+ 75% C
Risk Adjusted Return 31.61% 72% C 59% D-
Market Capitalization 11.57B 95% A 88% B+

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.